

NERVE-MAST CELL-NERVE GROWTH FACTOR LINK: THE MAST CELL AS YIN-YANG MODULATOR IN INFLAMMATION AND FIBROSIS

"Perhaps the situation at present is similar to that of the Holy elephant which had a hundred names, the real one being the hundred and first, known only to the elephant himself."

Albert Szent-Gyorgyi

Retrospect and Apology. In: Milhorat AT, editor. Exploratory concepts in muscular dystrophy and related disorders. New York, Excerpta Medica Foundation, 1966; 112-114

- Inflammation and fibroproliferation are biological responses aiming at recovering from injury. Wound healing is considered a paradigm of such a homeostatic phenomenon. However, what begins as a protective response, in excess becomes a damaging process we call chronic inflammatory-fibroproliferative disease.

Celsus's description (1st century AD) of inflammation signs includes *rubor et tumor cum calor et dolor*. For many years the inflammatory process has been thought of purely in terms of interactions involving leukocyte infiltration and fibroblast activation. Increasingly, however, neural cells have been shown to play a particularly important role in it, including interactions between nerves and mast cells (MC) (1-3). The article by Aloe *et al* (4) in this volume of *Biomedical Reviews* sheds considerable light on the potential significance of MC and nerve growth factor (NGF) in autoimmune-inflammatory diseases.

Historically, the discovery of MC is usually attributed to Paul Ehrlich in 1878, although these cells were first recognized by von Recklinghausen in 1863. Ehrlich observed that MC were commonly located in connective tissue near blood vessels and *nerves*, as well as in *inflammatory and tumor lesions*. At present there is evidence that (i) MC can be classified into connective tissue and mucosal subsets, and (ii) MC synthesize and, when activated, release biologically active molecules, e.g. eicosa-

noids, cytokines and growth factors, including the neurotrophic factors NGF (5) and leukemia inhibitory factor (LIF) (2,3). Last but not least, connective tissue MC are the richest cellular source of heparin proteoglycan, histamine, tryptase and chymase (6), and preformed, secretion granule-stored tumor necrosis factor- α (TNF- α), a highly potent inflammatory and fibrogenic cytokine (1).

The recent great advance relevant to MC studies occurred in 1977 when Aloe and Levi-Montalcini established the NGF-induced MC proliferation in different tissues of NGF-injected rats (7). This insight into the biology of NGF gives a special meaning to the nerve-MC bidirectional link, involving an immunotrophic action of the classical neurotrophin NGF (Fig.1). Further, MC-fibroblast interactions (8) and mast cell growth factor (MGF; synonyms: stem cell factor, c-kit ligand; see Bankl *et al* [9] in this volume of *Biomedical Reviews*) were recognized to play a pivotal role in the biology of MC. Even more intriguing is the possibility that the immunotrophin MGF exerts a neurotrophic action (10). Thus the nerve-MC bidirectional link was further extended (Fig.2). These new concepts about MC, i.e. paracrine/autocrine interactions between nerves and MC (1-3), MC and fibroblasts (8), and nerves, MC and effector cells (11), are now considered not only in allergic, parasitic and neoplastic reactions, but also in a number of disease processes featured by inflammation and fibrosis (Table 1, Refs shown in parentheses).




Figure 1. Mast cells (MC) are source of and target for nerve growth factor (NGF).




Figure 2. The nerve (N)-mast cell (MC) bidirectional link also involves both neurotrophic and immunotrophic actions of nerve growth factor (NGF) and mast cell growth factor (MGF).

Possible ways of interactions between nerves, MC and cytokines, including neurotrophic factors, in the development of inflammation and fibrosis are schematically presented in Fig.3,4 (Refs shown in parentheses). We, as Aloe *et al* (4), suppose that a discordant equilibrium, in which MC-derived inflammatory and fibrogenic stimulators exceed inhibitors, participates in progression of inflammation and fibrosis. Thus, MC via synthesis and release of such molecules may be considered a modulator operating in a *yin-yang* manner in the regression, delay, or progression of these disease processes (Table 2, Refs shown in parentheses). Of course, other immune cells, e.g. macrophages and lymphocytes, as well as their interactions with the neuroendocrine system (3 9), may also be particularly important in this aspect. In the context of this Editorial, it is worth mentioning that the immunotrophic action of NGF involves these immune cells too (4, their Refs 37-47).

A lot of issues can be raised in relation to the possible participation of nerve-MC-NGF-MGF link in the pathogenesis of inflammatory-fibroproliferative diseases listed in Table 1. For example, Aloe *et al* (4) present data of correlative increase in MC number and NGF level in autoimmune diseases, but a possible involvement of MGF remains unreported yet. Similarly, MGF action on cardiac MC was studied by Bankl *et al* (9) and Sperr *et al* (40). However, a possible importance of NGF in the biology of these cells was not appreciated, although a separate report clearly showed a significantly high NGF level in heart atrium (41), i.e. where a considerable amount of MC was found (9,40). In addition, recent reports show that NGF and other neurotrophins (42), including LIF (35), play an important role in regulating the response of vascular smooth muscle cells to injury. Again, in MC-rich atherosclerotic lesions (22,23), neither NGF nor MGF were examined. Hopefully, an integrative research approach (cf Table 1) focusing on cardiovascular nerve-MC-NGF-MGF link may bring new insights into car-

Table 1. Mast cell-associated diseases featured by inflammatory-fibroproliferative responses

| Diseases | | |
|-------------------------------------|-----------------------------------|---|
| <i>Mast cell/NGF-associated</i> | <i>Mast cell/nerve-associated</i> | <i>Mast cell-associated</i> |
| rheumatoid arthritis (4,12) | rheumatoid arthritis (13) | scleroderma (6) |
| multiple sclerosis (4,12) | gout (13) | pulmonary fibrosis (14,20) |
| systemic sclerosis (4,12) | bronchial asthma (2,14) | liver cirrhosis (21) |
| systemic lupus erythematosus (4,12) | chronic rhinitis (15) | atherosclerosis (22,23) |
| | Crohn's disease (2,13) | chronic graft-versus-host diseases (24) |
| | chronic ulcerative colitis (2,13) | keloid (19) |
| | oral mucosa inflammation (16) | Behçet's disease (19) |
| | temporal arteritis (17,18) | idiopathic male infertility (25) |
| | cluster headache (17,18) | interstitial cystitis (26) |
| | psoriasis (6,19) | Duchenne muscular dystrophy (27) |
| | lichen planus (6,19) | |




Figure 3. Cell-mediator interactions leading to inflammation and angiogenesis. *N* - neural cell, *MC* - mast cell, *PMN* - polymorphonuclear leukocyte, *EC* - endothelial cell, *SP* - substance P, and *CGRP* - calcitonin gene-related peptide (these are shown as examples of well-known proinflammatory neuropeptides), *IL-1* - interleukin-1, *bFGF* - basic fibroblast growth factor. For the rest abbreviations, see the text.




Figure 4. Cell-mediator interactions leading to proliferation and fibrosis. *N* - neural cell, *MC* - mast cell, *F* - fibroblast, *TGF-β* - transforming growth factor-β, *Ang II* - angiotensin II. Note: (i) substance P exerts mitogenic effect both on fibroblasts and smooth muscle cells (31,32), and (ii) MC may also produce collagen (33).

Table 2. Mast cell-derived molecules as yin-yang modulators in inflammation and fibrosis

| Yin (inhibitory counterpart) | Yang (stimulatory counterpart) |
|---------------------------------|-----------------------------------|
| heparin* (34) | eicosanoids (1,14) |
| chymase*/SP↓ (6,14) | chymase/procollagenase ↑ (37) |
| NGF (4,12) | chymase/Ang II ↑ (6,14) |
| LIF (35) | tryptase (30) |
| IL-4 (4) | histamine (38) |
| VIP (36) | TNF-α (1,2,6) |
| NO (11) | IL-1 (1,2,6) |
| | bFGF (29) |
| | TGF-β (1,2) |

*Note: this molecule may have both yin and yang potential. VIP - vasoactive intestinal polypeptide, NO - nitric oxide.

diovascular diseases of inflammatory-fibroproliferative nature (11,43). Perhaps, "we are already beginning to witness the change" (39) in our understanding of inflammation and fibrosis, as well as other nerve-MC-NGF-associated phenomena. A few years ago, it would seem premature to think that the submandibular gland, the richest source of NGF and a densely innervated effector tissue that also contains significant amount of MC, may produce molecules involved in regulation of inflammatory (44, also see Mathison [45] in this volume of *Biomedical Reviews*) and behavioral (46,47) responses. In effect, optimization of mechanisms for maintaining and/or restoring nerve-MC-NGF-MGF homeostatic functions following tissue inflammatory stimuli may lead to the development of new, MC-directed therapies for inflammatory-fibroproliferative diseases. Examples include angiotensin-converting enzyme inhibitors (21), MC stabilizing drugs (24,38), opioid receptor antagonists (36), anti-TNF-α drugs (48-51), adenosine A₃-receptor antagonists (52), histamine H₃-receptor agonists (53), and tryptase inhibitors (54).

Of course, the questions to be addressed remain rather more than the answers provided. This, in view of the Szent-Gyorgyi's thought at the beginning of this Editorial, means that we already are aware of the names of dozens of cells and molecules that govern inflammation and fibroproliferation. And, hopefully, we are forwarding to the hundred and first name.

In further studies we would try to pursue whether MC will prove to stand for "master cell" (1), "the immune gate to the brain" (55), and *yin-yang* modulator in inflammation and fibrosis. And, even more intriguing is whether the inflammatory-fibroproliferative response is at least in part a neural-mastokine phenomenon.

George N. Chaldakov¹, Peter I. Ghenev², Kamen Valchanov^{1,2}, Anton Tonchev^{1,2}, and Ruzha Pancheva^{1,2}

*laboratory of Electron Microscopy,
Department of Anatomy and Histology,
^Department of General and Clinical Pathology,
Medical University of Varna
BG-9002 Varna
Bulgaria*

REFERENCES

- Galli SJ. New concepts about the mast cell. *New Engl J Meet* 1993; 328:257-265
- Marshall JS, Bienenstock J. The role of mast cells in inflammatory reactions of the airways, skin and intestine. *Curr Opin Immunol* 1994; 6: 853-859
- Williams RM, Bienenstock J, Stead RH. Mast cells: the neuroimmune connection. In: Marone G, editor. Human basophils and mast cells: biological aspects. *Chem Immunol* 1995; 61: 208-235
- Aloe L, Tuveri M-A, Angelucci F. Nerve growth factor, mast cells and arthritis. *BiomedRev* 1995; 4: 7-14
- Leon A, Buriani A, Toso RD, Fabbi M, Romanello S, Aloe L. Mast cells synthesize, store, and release nerve growth factor. *Proc Natl Acad Sci USA* 1994; 91: 3739-3743
- Harvima IT, Horsmanheimo L, Naukkarinen A, Horsmanheimo M. Mast cell proteinases and cytokines in skin inflammation. *Arch Dermatol Res* 1994; 287: 61-67
- Aloe L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. *Brain Res* 1977; 133: 358-366
- Levi-Schaffer F, Rubinchik E. Mast cell/fibroblast interactions. *Clin Exp Allergy* 1994; 24: 1016-1021
- Bankl HC, Radaszkeiwicz T, Valent P. Mast cells and mast cell growth factor: possible role in auricular thrombosis. *BiomedRev* 1995; 4: 29-34
- Carnahan IF, Patel DR, Miller JA. Stem cell factor is a neurotrophic factor for neural crest-derived chick sensory neurons. *JNeurosci* 1994; 14: 1433-1440
- Chaldakov GN, Ghenev PI, Andonov M, Valchanov K, Tonchev A, Pancheva R. Neural-immune-effector (NIE) cross-talk in vascular trophobiology: proposal for new and not yet exploited purinergic regulatory mechanisms. *BiomedRev* 1994; 3: 81-86
- Aloe L, Skaper SD, Leon A, Levi-Montalcini R. Nerve growth factor and autoimmune diseases. *Autoimmunity* 1994; 19: 141-150
- Marshall JS, Wasserman S. Mast cells and the nerves - potential interactions in the context of chronic disease. *Clin Exp Allergy* 1995; 25: 102-110
- Warner JA, Kroegel C. Pulmonary immune cells in health and disease: mast cells and basophils. *EurRespirJ* 1994; 7: 1326-1341
- Changqing Z, Zhengde T, Jianyun X, Suping Z, Jiantian Q. An immunocytochemical study on relations between mast cell and peptidergic terminals in nasal mucosa of chronic rhinitis patients. *Chin Med J* 1995; 108: 606-609
- Matsson L, Norevall L-I, Forsgren S. Anatomic relationship between substance P- and CGRP-immunoreactive nerve fibers and mast cells in the palatal mucosa of the rat. *EurJOralSci* 1995; 103: 70-76
- Dimitriadou V, Henry P, Brochet B, Mathiau P, Aubineau P. Cluster headache: ultrastructural evidence for mast cell degranulation and interaction with nerve fibres in the human temporal artery. *Cephalalgia* 1990; 10: 221-228
- Aubineau P, Mathiau P. Can vascular headaches be triggered by the autonomic nervous system? In: Bevan RD, Bevan JA, editors. The human brain circulation. Humana Press, 1994; 433-444
- Weber S, Krtiger-Krasagakes S, Grabbe J, Zuberbier T, Czarnetzki BM. Mast cells. *IntJ Dermatol* 1995; 34:1-10
- Goto T, Befus D, Low R, Bienenstock J. Mast cell het-

- erogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. *Am Rev Respir Dis* 1984; 130: 797-802
21. Ramos SG, Montenegro AP, Goissis G, Rossi MA. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. *PatholInt* 1994; 44: 655-661
 22. Atkinson JB, Harlan CW, Harlan GC, Virmani R. The association of mast cells and atherosclerosis: A morphologic study of early atherosclerotic lesions in young people. *HumPathol* 1994; 25: 154-159
 23. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. *Circulation* 1995; 92: 1084-1088
 24. Nagler A, Segal V, Slavin S, Levi-Schaffer F. Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts. *Clin Exp Immunol* 1995; 100: 529-535
 25. Nagai T, Takaba H, Miyake K, Hirabayashi Y, Yamada K. Testicular mast cell heterogeneity in idiopathic male infertility. *Fertil Steril* 1992; 57: 1331-1336
 26. Theoharides TC, Flaris N, Cronin CT, Ucci A, Meares E. Mast cell activation in sterile bladder and prostate inflammation. *Int Arch Allergy Appl Immunol* 1990; 92: 281-286
 27. Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. *JNeural Sci* 1994; 122: 44-56
 28. Meininger CJ, Zertter BR. Mast cell and angiogenesis. *Semin Cancer Biol* 1992; 3: 73-79
 29. Qu Z, Eiebler JM, Powers MR, Galey T, Ahmadi P, Huang X-N, *et al.* Mast cell are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. *Am J Pathol* 1995; 147: 564-573
 30. Brown JK, Tyler CE, Jones CA, Ruoss SJ, Hartmann T, Caughey GH. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. *Am J Respir Cell Mol Biol* 1995; 13:227-236
 31. Nilsson J, von Euler AM, Dalsgaard CJ. Stimulation of connective tissue cell growth by substance P and substance K. *Nature* 1985; 315: 61
 32. Payan DG. Receptor-mediated mitogenic effects of substance P on cultured smooth muscle cells. *Biochem BiophysRes Commun* 1985; 130: 104
 33. Ruger B, Dunbar PR, Hasan Q, Sawada H, Kittelberger R, Greenhill N, *et al.* Human mast cells produce type Vtfl collagen *in vivo*. *Int J Exp Pathol* 1994; 75: 397-404
 34. H0gasen AKM, Abrahamsen TG. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. *ThrombRes* 1995; 80: 179-184
 35. Moran CS, Campbell JH, Simmons DE, Campbell GR. Human leukemia inhibitory factor inhibits development of experimental atherosclerosis. *Atheroscler Thromb* 1994; 14: 1356-1363
 36. Tuncel N. Mast cells, vasoactive intestinal peptide (VIP), and the hemorrhagic shock: a possible relationship? *BiomedRev* 1993; 2: 37-46
 37. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu⁸⁴-Thr⁸⁴ bond by mast cell chymase. *JBiol Chem* 1994; 269: 18134-18140
 38. Kanwar S, Kubes P. Ischemia/reperfusion-induced granulocyte influx is a multistep process mediated by mast cells. *Microcirculation* 1994; 1: 175-182
 39. Blalock JE. The syntax of immune-neuroendocrine communication. *Immunol Today* 1994; 15: 504-511
 40. Sperr WR, Bankl HC, Mundigler G, Klappacher G, GroBschmidt K, Agis H, *et al.* The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. *Blood* 1994; 84: 3876-3884
 41. Korsching S, Thoenen H. Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: Correlation with density of sympathetic innervation. *Proc NatlAcadSci USA* 1983; 80: 3513-3516
 42. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo E, Mahadeo D, *et al.* Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. *Am J Pathol* 1995; 147: 309-324
 43. Chaldakov GN, Valchanov K, Tonchev A, Ghenev PI.

- 6 e association of mast cells and atherosclerosis: new insights into mast cells in atherogenesis [letter]. *Hum Pathol* 1995; 26: 1286
44. Mathison R, Davison JS, Befus AD. Neuroendocrineregulation of inflammation and tissue repair by submandibular gland factors. *Immunol Today* 1994; 15: 527-532
 45. Mathison R. The submandibular glands: a role in homeostasis and allostasis. *Biomed Rev* 1995; 4: 61-69
 46. Alleva E, Aloe L, Bigi S. An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates. *RevNeurosci* 1993; 4: 41-62
 47. Chaldakov GN, Valchanov K, Tonchev A. Neural-immune-effector trophobiology: possible implications in psychology of the allergic patient [letter]. *Allergy*. In press
 48. Chaldakov GN. Antitubulins - a new therapeutic approach for atherosclerosis? *Atherosclerosis* 1982; 44: 385-390
 49. Tiegs G, Freudenberg MA, Galanos C, Wendel A. Colchicine prevents tumor necrosis factor-induced toxicity *in vivo*. *Infection Immunol* 1992; 60: 1941-1945
 50. Chaldakov GN. An antitumour necrosis factor therapy. *AIDS* 1992; 6: 439-440
 51. Anaya J-M, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: An antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. *J Rheumatol* 1995; 22: 595-599
 52. Linden J. Cloned adenosine A₁ receptors: pharmacological properties, species differences and receptor functions. *TrendsPharmacol Sci* 1994; 15: 289-306
 53. Dimitriadou V, Rouleau A, Tuong MDT, Newlands GIF, Miller HRP, Luffau G. *et al*. Functional relationship between mast cells and C-sensitive nerve fibers evidenced by histamine H₁-receptor modulation in rat lung and spleen. *C/m* 5c/1994; 87: 151-163
 54. Tanaka RD, Clark JM, Warne RL, Abraham WM, Moore WR. Mast cell tryptase: a new target for therapeutic intervention in asthma. *Int Arch Allergy Immunol* 1995; 107:408-409
 55. Theoharides TC. Mast cells: the immune gate to the brain. *Life Sci* 1990; 46: 607-617